Related Experiment Video
Updated: Jun 21, 2025
12:41
Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat
Published on: August 28, 2021
4.2K
Dexmedetomidine for Reducing Mortality in Patients With Septic Shock: A Randomized Controlled Trial (DecatSepsis)
Ahmed Ragab Ezz Al-Regal1, Eyad Ahmed Ramzy1, Amer Abd Allah Atia1
1Department of Anesthesiology and Intensive Care and Pain Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Chest
|July 14, 2024
Summary
Dexmedetomidine may reduce mortality in septic shock patients. This study found it lowered heart rate, epinephrine use, atrial fibrillation, and inflammation markers, though it was underpowered for mortality.
Area of Science:
- Critical Care Medicine
- Pharmacology
- Intensive Care
Background:
- Sepsis and septic shock are associated with a hyperadrenergic stress response.
- Understanding interventions to mitigate this response is crucial for patient outcomes.
Purpose of the Study:
- To investigate if dexmedetomidine decatecholaminization reduces in-hospital mortality in septic shock patients.
- To evaluate the effect of dexmedetomidine on heart rate and other clinical markers.
Main Methods:
- An open-label randomized controlled trial involving 90 septic shock patients with heart rate > 90 bpm.
- Dexmedetomidine infusion targeted a heart rate of 60-90 bpm for 48 hours.
- Secondary outcomes included vasopressor use, APACHE II score, atrial fibrillation, and CRP levels.
Main Results:
- Dexmedetomidine significantly reduced mean heart rate by 11.2 bpm.
- A trend towards reduced in-hospital mortality was observed (RR 0.68, P=0.091).
- Significant reductions were noted in epinephrine infusion rescue, persistent atrial fibrillation, APACHE II score, and C-reactive protein levels.
Conclusions:
- The study was underpowered to definitively prove reduced in-hospital mortality or norepinephrine equivalent dose.
- Dexmedetomidine shows promise in reducing key complications associated with septic shock, including epinephrine rescue, AF, and inflammatory markers.
